Lack of interleukin-1 receptor antagonist modulates plaque composition in apolipoprotein E-deficient mice

被引:133
作者
Isoda, K
Sawada, S
Ishigami, N
Matsuki, T
Miyazaki, K
Kusuhara, M
Iwakura, Y
Ohsuzu, F
机构
[1] Natl Def Med Coll, Tokorozawa, Saitama 3598513, Japan
[2] Univ Tokyo, Inst Med Sci, Ctr Med Expt, Tokyo, Japan
关键词
atherosclerosis; immune system; inflammation; interleukins; macrophage;
D O I
10.1161/01.ATV.0000127025.48140.a3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective - Interleukin (IL)-1 plays an important role in atherosclerosis. IL-1 receptor antagonist (IL-1Ra) is an endogenous inhibitor of IL-1. However, the role of IL-1Ra in the development of atherosclerosis is poorly understood. Methods and Results - Mice that lacked IL-1Ra (IL-1Ra-/-) were crossed with apolipoprotein E-deficient (E-/-) mice and formation of atherosclerotic lesions was analyzed after 16 weeks or 32 weeks consumption of a normal chow diet. This study focused on the comparison of atherosclerotic lesion between IL-1Ra+/+/apoE-/- (n = 12) and IL-1Ra(+/-)/apoE-/- mice (n = 12), because of the significantly leaner phenotype in IL-1Ra-/-/apoE-/- mice compared with the others. Interestingly, atherosclerotic lesion size in IL-1Ra+/-/apoE-/- mice at age 16 weeks was significantly increased (30%) compared with IL-1Ra+/+/apoE-/- mice (P < 0.05). At 32 weeks, the differences of lesion size between these mice failed to achieve statistical significance. However, immunostaining demonstrated an 86% (P < 0.0001) increase in the MOMA-2- stained lesion area of IL-1Ra+/-/apoE-/- mice. In addition, alpha-actin staining in these lesions was significantly decreased (-15%) compared with those in IL-1Ra+/+/apoE-/- mice (P < 0.05). Conclusions - These results suggest an important role of IL-1Ra in the suppression of lesion development during early atherogenesis and furthermore indicate its role in the modulation of plaque composition.
引用
收藏
页码:1068 / 1073
页数:6
相关论文
共 35 条
[1]  
AREND WP, 1994, J IMMUNOL, V153, P4766
[2]  
BEVILACQUA MP, 1985, AM J PATHOL, V121, P394
[3]   INTERLEUKIN-1 (IL-1) INDUCES BIOSYNTHESIS AND CELL-SURFACE EXPRESSION OF PROCOAGULANT ACTIVITY IN HUMAN VASCULAR ENDOTHELIAL-CELLS [J].
BEVILACQUA, MP ;
POBER, JS ;
MAJEAU, GR ;
COTRAN, RS ;
GIMBRONE, MA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1984, 160 (02) :618-623
[4]   T and B lymphocytes play a minor sole in atherosclerotic plaque formation in the apolipoprotein E-deficient mouse [J].
Dansky, HM ;
Charlton, SA ;
Harper, MM ;
Smith, JD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (09) :4642-4646
[5]   Genetic alterations of IL-1 receptor antagonist in mice affect plasma cholesterol level and foam cell lesion size [J].
Devlin, CM ;
Kuriakose, G ;
Hirsch, E ;
Tabas, I .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (09) :6280-6285
[6]   Interleukin-1 receptor antagonist expression in human endothelial cells and atherosclerosis [J].
Dewberry, R ;
Holden, H ;
Crossman, D ;
Francis, S .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (11) :2394-2400
[7]  
Dinarello C A, 1998, Int Rev Immunol, V16, P457, DOI 10.3109/08830189809043005
[8]   Biologic basis for interleukin-1 in disease [J].
Dinarello, CA .
BLOOD, 1996, 87 (06) :2095-2147
[9]   Vascular proliferation and atherosclerosis: New perspectives and therapeutic strategies [J].
Dzau, VJ ;
Braun-Dullaeus, RC ;
Sedding, DG .
NATURE MEDICINE, 2002, 8 (11) :1249-1256
[10]   PRIMARY STRUCTURE AND FUNCTIONAL EXPRESSION FROM COMPLEMENTARY-DNA OF A HUMAN INTERLEUKIN-1 RECEPTOR ANTAGONIST [J].
EISENBERG, SP ;
EVANS, RJ ;
AREND, WP ;
VERDERBER, E ;
BREWER, MT ;
HANNUM, CH ;
THOMPSON, RC .
NATURE, 1990, 343 (6256) :341-346